The global diagnostics market is undergoing radical change; novel technologies
driven by miniaturization and advances in genomics will enhance the role of
diagnostics in the healthcare market, allowing more tests to be performed at
the point-of-care and facilitating the shift towards personalized medicine.
"Innovation in Diagnostics" examines the advances in the rapidly growing field
of molecular technologies that are enabling personalized healthcare to move
into mainstream medicine. New opportunities in infectious disease testing,
molecular oncology and pharmacogenomics are explored in detail, enabling you
to understand the forces that are driving in vitro diagnostics (IVDs) into
centre stage of the healthcare arena. Understand the changing relationship
between IVD companies and the pharmaceutical industry, assess the convergence
of IVDs and medical imaging, and develop an understanding of new technologies
that will influence diagnostic product development and drug development
programs.
Table of Contents
Executive Summary
Introduction to diagnostics
Challenges and opportunities in diagnostic innovation
Molecular technology innovations
Innovation in infectious disease diagnostics
Personalized medicine
Point-of-care testing
Competitive landscape
Chapter 1 Introduction to diagnostics
Summary
Introduction
The global IVD market
Market segments
Market dynamics
Market growth
Key IVD players
Industry profile
Overview of diagnostic technologies
Immunoassays
Nucleic acid (NA) assays
Biosensors
Microarrays
Future trends
Chapter 2 Challenges and opportunities in diagnostic innovation
Summary
Introduction
A changing healthcare environment
Challenges & opportunities
Regulatory hurdles
Reimbursement
Technology requirements
Connectivity
Communication
New partnerships/new players
Chapter 3 Molecular technology innovations
Summary
Introduction
IVD technologies
PCR
FISH
Arrays
Nanotechnology
DNA methylation
DNA biosensors
Chapter 4 Innovation in infectious disease diagnostics
Summary
Introduction
Emerging infections
Avian influenza H5N1
SARS
Multiple detection of infectious agents
Future challenges
Hospital-acquired infections
Gonorrhea
Early onset sepsis
Other infections
Chapter 5 Personalized medicine
Summary
Introduction
Imaging: part of the Dx+PGx+Rx equation
Pharmacogenomics
Clinical application of pharmacogenomics
Pharmacogenetic tests
Case Study: AmpliChip CYP450
Other pharmacogenetic tests
Biomarkers
Case study: Diabetes
Case study: Heart disease
Oncology
Breast cancer
Colorectal cancer
Leukemia
Lung cancer
Prostate cancer
Future challenges
Chapter 6 Point-of-care testing
Summary
Introduction
Blood glucose tests
Case study: Scout test for diabetes screening
Infectious diseases
Rapid Step B test
Urinary tract infection (UTI) biosensor
Active tuberculosis (TB)
Cardiac diagnostics
Blood coagulation
Cardiac markers
Direct LDL cholesterol test
Stroke
Bladder cancer rapid test
HIV home tests
Future challenges
Chapter 7 Competitive landscape
Summary
Introduction
Key mergers & acquisitions
Competitive landscape
Pharma companies with Dx divisions
Roche Diagnostics
Diabetes Care
Centralized Diagnostics
Molecular Diagnostics
Near Patient Testing
Applied Science
Product Pipeline
Abbott
Diabetes Care
Immunodiagnostics, clinical chemistry and hematology
Molecular Diagnostics
Point-of-Care
MedTech companies with Dx divisions
Becton Dickinson
Diagnostics
Biosciences
Dx Specialists
Gen-Probe
Clinical Diagnostics
Blood Screening
Molecular Diagnostics
Inverness Medical Innovations (IMI)
Consumer Diagnostics Products
Professional Diagnostics Products
Research & Development
Acquisitions
Tm Bioscience
Human Genetics
Infectious disease
PGx
Technology specialists
Affymetrix
Collaborations
Competition
Nanogen
Chapter 8 Appendix
Index
※この商品は英文にてご提供いたします。
【 英文市場調査報告書 】
診断技術の発展：個人化医療を促進する次世代型分子診断およびポイントオブケア診断
Innovations in Diagnostics: Next generation molecular and point-of-care diagnostics driving personalized healthcare
出版日: 2006/09
医薬品
その他のカテゴリ
FAQ